A role for helper T cells in the induction of pathogenic lupus autoantibodies is increasingly supported by data from studies of murine lupus and patients with systemic lupus erythematosus (SLE). However, the poor in vitro function of SLE T cells has hampered the identification and characterization of autoantigen-specific T cells. We used recombinant fusion proteins to study the T cell proliferative response of 31 lupus patients and 27 healthy subjects to a well-characterized SLE autoantigen, the ribosomal P2 protein. Although PBMC from SLE patients showed marked impairment in the proliferative response to the common recall antigen tetanus toxoid when compared with normal subjects, a significantly greater proportion of SLE patients (32%) than normal individuals (0%) showed a T cell response to a recombinant P2 fusion protein. When the SLE patients were subgrouped according to the presence of serum anti-P autoantibody, 7 of 10 anti-P antibody-positive patients, but 0 of 20 anti-P antibody-negative SLE patients, demonstrated > 2,000 cpm [3H]thymidine incorporation and a P2 stimulation index > 5. The specificity of the T cell proliferative response for the P2 protein was confirmed by studies using a second recombinant human P2 fusion protein and by the specific activation of P2-primed T cells by recombinant P2 in secondary cultures. Moreover, the T cell proliferative response to the P2 autoantigen was mediated by CD4-positive T cells and was inhibited by anti-MHC class II antibodies. These data demonstrate the presence of autoantigen-specific T helper cells in patients with SLE and suggest that these T cells drive the production of autoantibodies by B lymphocytes. (J. Clin. Invest. 1994.94:345-352.) 
Introduction
Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, is characterized by B cell activation, hypergammaglobulinemia, and the presence of serum autoantibodies. Although the hypergammaglobulinemia of SLE is poly-clonal, certain autoantibodies are present at strikingly high titers and bind to a limited number of self proteins (1) . Particularly frequent are antibodies specific for proteins contained within complex intracellular particles, such as nucleosomes, small nuclear ribonucleoproteins (snRNPs),' and ribosomes. Autoantibodies are thought to be responsible for many of the clinical manifestations of SLE, including glomerulonephritis, arthritis, and serositis.
The mechanisms that drive autoantibody production in SLE remain uncertain. However, accumulating evidence suggests that this process is both autoantigen driven and T cell dependent. Supporting an essential role for autoantigens in stimulating autoantibody production by B cells are the observations that SLE antisera react with several proteins located within the same particle and with multiple epitopes on the same antigen, and that autoantibodies to different epitopes on the same antigen fluctuate in parallel (for review see reference 2). Evidence supporting an essential role for T cells in SLE has predominantly been obtained from murine lupus (for review see reference 3) and includes the observations that neonatal thymectomy prevents or markedly ameliorates the SLE-like syndrome in both MRL and NZB/W Fl mice; treatment of NZB/W FI and MRL/lpr mice with the anti-L3T4 monoclonal antibody reactive with the helper T cell (Th) subset abrogates their systemic autoimmune disease; and the transfer of parental T cells into F1 recipient animals can result in a lupus-like syndrome (4) . In human SLE, the evidence implicating T cells is indirect. The pathogenic antibodies are of the IgG isotype and are encoded by immunoglobulin genes that have undergone somatic mutation (5) .
Although efforts to characterize autoantigen-specific T cells in organ-specific autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Graves' disease have met some success, it has been difficult to demonstrate that the proteins recognized as antigens by lupus autoantibodies can activate SLE T cells. These difficulties are due in part to numerous in vitro SLE T cell functional deficits and to difficulties in purifying large amounts of native antigens by biochemical methods. The recent cloning and production in large quantities of several SLE autoantigens provide the opportunity to study the T cell response to these autoantigens. One well-characterized SLE antigen is the ribosomal P2 phosphoprotein (for review see reference 6) . Approximately 15% of all SLE patients, and the majority of patients with lupus psychosis (7), have anti-P antibodies that bind to a shared epitope on the carboxyl-terminal portion of PO, P1, and P2. We report our analysis of the T cell proliferative response to the recombinant P2 fusion protein in SLE patients and healthy individuals.
Methods
Study subjects. Patients with SLE (n = 29), meeting at least four of the American Rheumatism Association revised criteria for the diagnosis of SLE (8) , and patients with LE with discoid features (n = 2) were followed at The Hospital for Special Surgery Rheumatic Disease Clinic. Peripheral blood samples were obtained with permission of the patients. Apart from the specific attempt to recruit all lupus patients positive for anti-P antibodies, no other selection criteria were used for the inclusion of SLE patients in this study. Normal controls included 27 healthy approximately age-matched volunteers.
Expression of P2-(3-galactosidase (P2-,/-gal) and P2-TrpEfusion proteins (rHuP2). The lysogenic Escherichia coli strain Y 1089 was infected with a recombinant lambda phage containing the cDNA encoding the full-length human P2 protein (9) . Protein expression was induced by a temperature shift to 450C and by 10 mM isopropyl/thiogalactosidase. Full-length human P2 fused to the TrpE protein and the control TrpE protein were created in the pATH series of plasmids (10) . Proteins were expressed in E. coli strain HB101 after induction with 50 1M indoleacylic acid as described previously ( 11) . To isolate overexpressed proteins, bacteria were harvested by centrifugation, and the insoluble proteins were recovered by the method of Adam et al. (12) . As reported previously, the recombinant proteins were 90-95% pure as determined by densitometric scanning of Coomassie blue-stained polyacrylamide gels (9, 1 1 ). Total protein was measured by the method of Bradford (13) . rHuP2 and control proteins were used at a final concentration 20 jig/ml in culture medium.
Additional antigens. Tetanus toxoid (TT; State Laboratory Institute, Jamaica Plain, MA) was used at a final concentration of 10 jig protein/ ml. Intact human ribosomes were isolated from HeLa cytoplasmic extracts by discontinuous sucrose density ultracentrifugation as described (14) and used at a final concentration of 25-50 jug/ml. The P2 protein comprises 2% of the ribosomal protein preparation.
Anti-P ELISA. The ELISA was performed as described (9) . Briefly, microtiter wells were coated with 200 ng of rHuP2 at 4°C overnight. The plates were washed with PBS (0.15 M NaCl buffered with 10 mM phosphate, pH 7.4) and then blocked with 1% BSA for 1 h at room temperature. Serum samples (diluted 1:500 in PBS containing 0.05% Tween-20 and 10% normal goat serum) were added to the wells. The plates were incubated at 37°C for 3 h. Alkaline phosphatase-conjugated goat anti-human IgG, diluted 1:1,000 in PBS containing 10% normal goat serum, was then added to the plates and incubation was performed for an additional hour at 37°C. The mechanisms. Most SLE patients also showed poor proliferative responses to both rHuP2 and to the control fusion protein (Table  I) . However, when the proliferative responses to rHuP2 and the control protein were compared in the same individuals, the total SLE and anti-P+, but not the anti-P-, SLE patients demonstrated significantly higher responses to the autoantigen (P < 0.02).
To address whether SLE anti-P+ patients had a relatively greater response to rP2 than the control study groups, the results were expressed as a Stimulation Index (SI) (calculated from rHuP2 cpm/control fusion protein cpm). The SI was used to reduce the influence of the slightly higher background proliferation (with medium and the control protein) observed in normal controls and the reduced capacity of SLE T cells to respond to a recall antigen as described above (Table I) . To Table I . Only individuals showing proliferative responses > 2,000 cpm were included in this analysis.
subjects whose PBMC incorporated > 2,000 cpm, only 3 (14%) had a P2 SI > 3 and none had a SI > 5. Thus, in spite of their marked impairment in antigen-specific T cell proliferation, as documented by the poor response to TT, more than one third of the SLE patients tested showed an augmented T cell response to rHuP2 when compared with the response to control protein.
Of the nine anti-P+ SLE responders, seven had a P2 SI > 5 (Fig. 2) . None of the 20 anti-P-patients had a P2 SI > 5. When the SI was compared between anti-P+ (SI, 10.2±9.2) and anti-P-SLE patients (SI, 1.8±1.0), a striking difference was observed (P < 0.005). These results demonstrate an association between the presence of serum autoantibody specific for the P protein and the capacity of an individual's T cells to respond in vitro to the P2 fusion protein.
To further investigate the proliferative response to the P autoantigen in the anti-P antibody-positive SLE patients, a dose-response study was performed (Fig. 3) . PBMC from a different SLE patient were cultured for 10 d with rHuP2 and the low density (activated T cell-enriched) and high density (unactivated T cell-enriched) populations were isolated on a Percoll density gradient (Fig. 6, B) . The low density, but not the high density, primed T cells were retriggered to proliferate when incubated for 3 d in secondary culture with rHuP2, irradiated autologous B cell line cells, and IL-2. These experiments clearly demonstrate that an antigen-specific secondary T cell response can be triggered in SLE T cells primed with the ribosomal P2 autoantigen.
Discussion
Increasing evidence supports the idea that autoantigen-specific T cells play an important role in human autoimmune diseases. 27) . Although these associations may in part be explained by independent associations with MHC class III products, class II polymorphisms are strongly associated with the presence of specific autoantibodies in SLE (27) . Almost all patients with anti-Ro (SSA) antibodies had a glutamine at position 34 and/or a leucine at position 26 at the outermost domains of the HLA DQA1 and DQB1 chains, respectively (28) . Because these residues map to the floor of the putative MHC class H antigen binding groove, this association is most readily explained by the preferential presentation of particular autoantigen-derived peptides by specific MHC class II products to T cells. Direct evidence for the involvement of T cells in autoantibody production in SLE and the closely related disease, mixed connective tissue disease, is, however, limited. CD4+, DRrestricted T cells from SLE patients have been propagated in vitro and found to provide help for the production of IgG anti-DNA autoantibodies by autologous B cells (29) . These Th cell lines proliferate in response to autologous antigen presenting cells, although their precise antigen specificity has not been defined. Recently, T cell proliferative responses to ribonucleoprotein-derived protein antigens adsorbed to nitrocellulose membranes (30) and to either native (31 ) or recombinant (32, 33) Ul-snRNP proteins in solution have been reported. Okubo et al. (32) demonstrated that T cell proliferation in response to a recombinant Ul-snRNP A fusion protein occurred almost exclusively in patients with anti-snRNP antibodies. Furthermore, they demonstrated inhibition of Ul-snRNP-stimulated T cell proliferation with anti-CD4 mAb reactive with the helper T cell subset and the presence of the responder T cells at relatively high frequency (1:4,000-1:23,000).
The production of large quantities of the recombinant human ribosomal P2 autoantigen (9) has allowed us to study an autoantigen-specific T cell response in patients with SLE. Despite a marked deficiency in T cell proliferation to the recall antigen tetanus toxoid, a significantly greater proportion of lupus patients had a T cell response to rHuP2 (arbitrarily defined as a greater than fivefold response compared with that obtained with the appropriate r control protein) compared with normal individuals. Most important, a significantly higher frequency of T cell proliferative responses to rHuP2 was observed in lupus patients cpm (x1O ) Figure 6 . rHuP2-primed SLE T cells are specifically retriggered by rHuP2 in secondary cultures. In experiment 1 (top), PBMC from an anti-P antibody-positive SLE patient were stimulated in primary culture with 10 A.g/ml P2-,l/-gal. After (35) and lupus psychosis (7) . Similarly, it is unlikely that drugs or disease activity influenced the results, because no significant differences in T cell proliferation to tetanus toxoid were observed in the anti-P antibody-positive and negative patient groups. Because the purity of the r proteins used in this study did not exceed 95%, we cannot exclude the possibility that some of the T cell proliferative responses observed resulted from trace bacterial contaminants in the cultures. However, proliferative responses to bacterial contaminants cannot explain why T cell responses were preferentially observed with P2 fusion proteins rather than the control bacterial proteins and why responses were greater in SLE patients with anti-P antibodies compared with patients without a serologic response to P2. Furthermore, the similar proliferative responses observed in individual patients to recombinant P2 fusion proteins with different fusion partners and proliferation in response to biochemically purified ribosomes in some anti-P-positive patients indicate that the T cell proliferation described here was predominantly initiated by recognition of peptides derived from the human ribosomal P2 protein. The lack of complete concordance between the T cell response to rHuP2 and the biochemically purified ribosomes may be due to differences in the quantity or form of the antigen or due to differences in the processing or presentation of the peptides by antigen presenting cells. In common with T cell proliferative responses to soluble foreign protein antigens, the P2-reactive cells were predominantly CD4 positive and the proliferative response was inhibited by mAb to MHC class H antigens. Of potential interest is the observation that anti-DQ, as well as anti-DR, mAb inhibited the autoantigen-induced T cell response whereas the response to TT was only inhibited by anti-DR mAb. Studies are currently in progress to examine whether specific MHC class H alleles can be identified in SLE patients with B and T cell responses to P2.
Recent analyses of the trimolecular complex formed by the interaction of the TCR, antigenic peptide, and the MHC class II molecule show that the variable regions of the TCR bind to a linear peptide of between 16 and 25 residues located within the groove formed by the alpha helices of the MHC molecules (36) . This being the case, it is difficult to explain how T cells are involved in the production of autoantibodies to nucleic acids in SLE. Possible mechanisms are suggested by murine studies showing "determinant spreading" in the course of a T cell immune response to autoantigen (37) and the recent demonstration that T cells activated by a foreign snRNP protein can drive the secretion of a linked set of autoantibodies reactive with other components of the murine snRNP particle (38) . It has been suggested that, once T cell tolerance to one protein component of a complex protein-nucleic acid particle is broken, the subsequent immune response may readily extend to other components of the particle (38) (39) (40) (41) . This expanded repertoire of antibody specificities could then include reactivity to nucleic acids as well as proteins and could explain the presence of anti-28S rRNA autoantibodies in 75% of SLE patients with anti-P (42, 43) . These models do not rule out a potential concomitant role for antigen-nonspecific activation of Th cells, as may occur on exposure to microbial superantigens, in the differentiation of nucleic acid-specific B cells (44) .
In conclusion, we have documented an autoantigen-specific T cell proliferative response in a high percentage of patients with serum autoantibodies directed against the ribosomal P2 protein. Characterization of the TCR genes and MHC restricting elements used by these cells, as well as investigation of their functional properties, should lead to considerable insight into the mechanisms of autoantibody production in systemic autoimmune disease.
